Karniol, I. G., Carlini, E. A., «The content of (-) 9 -trans-tetrahydrocannabinol (9 -thc) does not explain all biological activity of some Brazilian marihuana samples», in: Journal of Pharmacy and Pharmacology 24 (1972), 10, S. 833–834.

Thompson, G. R., Rosenkrantz, H., Schaeppi, U. H., Braude, M. C., «Comparison of acute oral toxicity of cannabinoids in rats, dogs and monkeys», in: Toxicology and Applied Pharmacology 25 (1973), S. 363–372.

Taylor, L., Gidal, B., Blakey, G., Tayo, B., Morrison, G., «A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects», in: CNS Drugs 32 (2018), 11, S. 1053–1067.

Grotenhermen, F., «Non-psychological adverse effects», in: Pertwee, R., ed., Handbook of Cannabis. Oxford: Oxford University Pres (2014), S. 674–691.

Jones, R.T., Benowitz, N., Herning, R.I., «The clinical relevance of cannabis tolerance and dependence», in: Journal of Clinical Pharmacology 21 (1981), S. 143–152.

Taylor, L., Crockett, J., Tayo, B., Checketts, D., Sommerville, K., «Abrupt withdrawal of cannabidiol (CBD): A randomized trial», in: Epilepsy & Behavior 104 (2020), Pt A, 106938.

https://elifesciences.org/articles/57591

See, G., «Anwendung der Cannabis indica in der Behandlung der Neurosen und gastrischen Dyspepsieen», in: Deutsche Medizinische Wochenschrift 16 (1890), 34, S. 771–774.

O’Shaugnessy, W. B., «On the preparations of the Indian hemp, or Gunjah», in: Provincial Medical Journal and Retrospect of the Medical Sciences (Nachdruck) 5 (1843), 123, S. 363–369.

Fronmüller, B., «Klinische Studien über die schlafmachende Wirkung der narkotischen Arzneimittel», Erlangen, 1869, S. 69.

Reynolds, J. R., «Therapeutic uses and toxic effects of Cannabis indica», in: The Lancet 1 (1890), S. 639.

Hartwich, C., «Hanf», in Hartwich, C., «Die menschlichen Genussmittel. Ihre Herkunft, Verbreitung, Geschichte, Anwendung, Bestandteile und Wirkung», Leipzig: Chr. Herm. Tauchnitz, 1911, S. 221–238.

Loewe, S., «Cannabiswirkstoffe und Pharmakologie der Cannabinole», in: Archiv für Experimentelle Pathologie und Pharmakologie 211 (1950), S. 175–193.

Fankhauser, M., Eigenmann, D., «Cannabis in der Medizin», Solothurn, Schweiz: Nachtschatten Verlag, 2020.

Curry, A., «Warum die Skythen heulten», in: National Geographic (2015), Heft 3, S. 26–27. Verfügbar online unter: https://www.nationalgeographic.de/geschichte-und-kultur/warum-die-skythen-heulten

Ren, M., Tang, Z., Wu, X., Spengler, R., Jiang, H., Yang, Y., Boivin, N., «The origins of cannabis smoking: Chemical residue evidence from the first millennium BCE in the Pamirs», in: Science Advances 5 (2019), 6, eaaw1391.

Fankhauser, M., «Kulturgeschichte der medizinischen Verwendung», in: Müller-Vahl, K., Grotenhermen, F. (Hrsg.), «Cannabis und Cannabinoide in der Medizin», Berlin: Medizinisch Wissenschaftliche Verlagsgesellschaft, 2019, S. 12–22.

ElSohly, M. «Chemische Bestandteile von Cannabis», in: Grotenhermen F. (Hrsg.), Cannabis und Cannabinoide. Pharmakologie, Toxikologie und therapeutisches Potential. Göttingen: Hans Huber, 2001 (1. Aufl.), 2004 (2. erweiterte und ergänzte Ausgabe), S. 45–55.

Palomares, B., Garrido-Rodriguez, M., Gonzalo-Consuegra, C., Gómez-Cañas, M., Saen- Oon, S., Soliva, R., Collado, J. A., Fernández-Ruiz, J., Morello, G., Calzado, M. A., Appendino, G., Muñoz, E., «Δ9-Tetrahydrocannabinolic acid alleviates collagen-induced arthritis: Role of PPARY and CB 1 receptors», in: British Journal of Pharmacology. 8. Jun 2020.

Russo, E. B., «Cannabis Therapeutics and the Future of Neurology», in: Frontiers in Integrative Neuroscience 12 (2018), S. 51.

Ligresti, A., Moriello, A. S., Starowicz, K., Matias, I., Pisanti, S., De Petrocellis, L., Laezza, C., Portella, G., Bifulco, M., Di Marzo, V., «Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma», in: Journal of Pharmacology and Experimental Therapeutics 318 (2006), 3, S. 1375–1387.

Espadas, I., Keifman. E., Palomo-Garo, C., Burgaz, S., García, C., Fernández-Ruiz, J., Moratalla, R. «Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson’s disease», in: Neurobiology of Disease (Juli 2020) Jul, 141: 104892.

Grotenhermen, F., «Phytocannabinoide», in: von Heyden, M., Jungaberle, H., Majić, T. (Hrsg.), Handbuch Psychoaktive Substanzen, Berlin: Springer, 2018, S. 659–668.

Jadoon, K. A., Ratcliffe, S. H., Barrett, D. A., Thomas, E. L., Stott, C., Bell, J. D., O’Sullivan, S. E., Tan, G. D., «Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study», in: Diabetes Care 39 (2016), 10, S. 1777–1786.

Rock, E. M., Limebeer, C. L., Parker, L. A., «Effect of cannabidiolic acid and ∆9-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema in a rodent model of inflammatory pain», in: Psychopharmacology (Berlin) 235 (2018), 11, S. 3259–3271.

Pretzsch, C. M., Voinescu, B., Lythgoe, D., Horder, J., Mendez, M. A., Wichers, R., Ajram, L., Ivin, G., Heasman, M., Edden, R.A. E., Williams, S., Murphy, D.G. M., Daly, E., McAlonan, G. M., «Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): a single dose trial during magnetic resonance spectroscopy», in: Translational Psychiatry 9 (2019), 1, S. 313.

Vigli, D., Cosentino, L., Raggi, C., Laviola, G., Woolley-Roberts, M., De Filippis, B., «Chronic treatment with the phytocannabinoid Cannabidivarin (CBDV) rescues behavioural alterations and brain atrophy in a mouse model of Rett syndrome», in: Neuropharmacology 140 (2018), S. 121–129.

Farha, M. A., El-Halfawy, O. M., Gale, R. T., MacNair, C. R., Carfrae, L. A., Zhang, X., Jentsch, N. G., Magolan, J., Brown, E. D., «Uncovering the Hidden Antibiotic Potential of Cannabis», in: ACS Infectious Diseases 6 (2020), 3, S. 338–346.

Wong, H., Cairns, B. E., «Cannabidiol, cannabinol and their combinations act as peripheral analgesics in a rat model of myofascial pain», in: Archives of Oral Biology 104 (2019), S. 33–39.

Komori, T., Fujiwara, R., Tanida, M., Nomura, J., Yokoyama, M. M., «Effects of citrus fragrance on immune function and depressive states», in: Neuroimmunomodulation 2 (1995), 3, S. 174–180.

Peana, A. T., Rubattu, P., Piga, G. G., Fumagalli, S., Boatto, G., Pippia, P., De Montis, M. G., «Involvement of adenosine A1 and A2A receptors in (-)-linalool-induced antinociception», in: Life Sciences 78 (2006), 21, S. 2471–2474.

Elisabetsky, E., Brum, L. F., Souza, D. O., «Anticonvulsant properties of linalool in glutamate-related seizure models», in: Phytomedicine 6 (1999), 2, S. 107–113.

Berger, M., Clarke, R. C., «Klassifizierung und Botanik von Cannabis», in: Müller-Vahl, K., Grotenhermen, F. (Hrsg.), Cannabis und Cannabinoide in der Medizin. Berlin: Medizinisch Wissenschaftliche Verlagsgesellschaft, 2019, S. 50–60.

Hazekamp, A., Fischedick, J. T., «Cannabis – from cultivar to chemovar», in: Drug Testing and Analysis 4 (2012), 7-8, S. 660–667.

Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., Howlett, A. C., «Determination and characterization of a cannabinoid receptor in rat brain», in: Molecular Pharmacology 34 (1988), 5, S. 605–613.

Müller-Vahl, K. R., Bindila, L., Lutz, B., Musshoff, F., Skripuletz, T., Baumgaertel, C., Sühs, K. W., «Cerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome», in: Neuropsychopharmacology (2020) 45(8), S. 1323–1329.

Russo, E. B., «Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes», in: Cannabis and Cannabinoid Research (2016) 1(1), S. 154–165.

Kataoka, K., Bilkei-Gorzo, A., Nozaki, C., Togo, A., Nakamura, K., Ohta, K., Zimmer, A., Asahi, T., «Age-dependent Alteration in Mitochondrial Dynamics and Autophagy in Hippocampal Neuron of Cannabinoid CB1 Receptor-deficient Mice». in: Brain Research Bulletin 160 (2020), S. 40–49.

Hazekamp, A., Ruhaak, R., Zuurman, L., van Gerven, J., Verpoorte, R., «Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol», in: Journal of Pharmaceutical Sciences 95 (2006), 6, S. 1308–1317.

Huestis, M. A., Henningfield, J. E., Cone, E. J., «Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana», in: Journal of Analytical Toxicology 16 (1992), 5, S. 276–282.

Frytak, S., Moertel, C. G., Rubin, J., «Metabolic studies of delta-9-tetrahydrocannabinol in cancer patients», in: Cancer Treatment Reports 68 (1984), 12, S. 1427–1431.

Grotenhermen, F., «Cannabidiol: Ein Cannabinoid mit Potenzial», Solothurn, Schweiz: Nachtschatten Verlag, 2017.

Hobbs, J.M., Vazquez, A.R., Remijan, N.D., Trotter, R.E., McMillan, T.V., Freedman, K.E., Wei, Y., Woelfel, K.A., Arnold, O.R., Wolfe, L.M., Johnson, S.A., Weir, T.L., «Evaluation of pharmacokinetics and acute anti-inflammatory potential of two oral cannabidiol preparations in healthy adults», in: Phytotherapy Research, 8. März 2020.

Patel, R.R., Barbosa, C., Brustovetsky, T., Brustovetsky, N., Cummins, T.R., «Aberrant epilepsy-associated mutant Nav1.6 sodium channel activity can be targeted with cannabidiol», in: Brain 139 (2016), Pt 8, S. 2164– 2181.

Hampson, A.J., Grimaldi, M., Axelrod, J., Wink, D., «Cannabidiol and (-)Delta-9-tetrahydrocannabinol are neuroprotective antioxidants», in: Proceedings of the National Academy of Sciences of the United States of America 95 (1998), 14, S. 8268–8273.

von Wrede, R., Moskau-Hartmann, S., Amarell, N., Surges, R., Erich Elger, C., Helmstaedter, C, «Plant derived versus synthetic cannabidiol: Wishes and commitment of epilepsy patients», in Seizure (2020) 80, S. 92–95.

https://www.arbeitsgemeinschaft-cannabis-medizin.de/

Biasutti, W. R., Leffers, K.S. H., Callaghan, R. C., «Systematic Review of Cannabis Use and Risk of Occupational Injury», in: Substance Use & Misuse. 2020: S. 1–13.

Grotenhermen, F., Häußermann, K., «Cannabis: Verordnungshilfe für Ärzte», Stuttgart: Wissenschaftliche Verlagsgesellschaft, 2019 (3. erweiterte Aufl.).

http://cannabis-med.org/nis/data/file/cannabissorten_inhaltsstoffe.pdf

Abrams, D. I., Jay, C. A., Shade, S. B., Vizoso, H., Reda, H., Press, S., Kelly, M. E., Rowbotham, M. C., Petersen, K. L., «Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial», in: Neurology 68 (2007), 7, S. 515–521.

Rog, D. J., Nurmikko, T. J., Friede, T., Young, C. A., «Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis», in: Neurology 65 (2005), 6, S. 812–819.

Pinsger, M., Schimetta, W., Volc, D., Hiermann, E., Riederer, F., Polz, W., «Nutzen einer Add-On-Therapie mit dem synthetischen Cannabinomimetikum Nabilone bei Patienten mit chronischen Schmerzzuständen – eine randomisierte kontrollierte Studie», in: Wiener klinische Wochenschrift 118 (2006), 11–12, S. 327–335.

Wilsey, B., Marcotte, T., Tsodikov, A., Millman, J., Bentley, H., Gouaux, B., Fishman, S., «A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain», in: The Journal of Pain 9 (2008), 6, S. 506–521.

Nicolodi, M., Sandoval, V., Torrini, A., «Therapeutic use of cannabinoids: dose finding, effects and pilot data of effects in chronic migraine and cluster headache», in: European Journal of Neurology 24 (2017), S. 287.

Reinert, A. E., Hibner, M., «Self-reported efficacy of cannabis for endometriosis pain», in: The Journal of Minimally Invasive Gynecology 26 (2019), 7, S. 27.

Fiz, J., Durán, M., Capellà, D., Carbonell, J., Farré, M., «Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life», in: PLoS One 6 (2011), 4, e18440.

Cuñetti, L., Manzo, L., Peyraube, R., Arnaiz, J., Curi, L., Orihuela, S., «Chronic pain treatment with cannabidiol in kidney transplant patients in Uruguay», in: Transplantation Proceedings 50 (2018), 2, S. 461–464.

Xu, D. Q., Dai, Y., Zhang, W. F., Wang, J. F., Wang, Y. Y., Zhang, Y., Zhao, Q. L., Li, X., «Rapid identification of MDMB-CHMINACA metabolites using Zebrafish and Human Liver microsomes as the Biotransformation system by LC-QE-HF-MS», in: Journal of Analytical Toxicology, 4. Februar 2020.

Nitecka-Buchta, A., Nowak-Wachol, A., Wachol, K., Walczyńska-Dragon, K., Olczyk, P., Batoryna, O., Kempa, W., Baron, S., «Myorelaxant Effect of Transdermal Cannabidiol Application in Patients with TMD: A Randomized, Double-Blind Trial», in: Journal of Clinical Medicine 8 (2019), 11, S. 1886.

Eskander, J.P., Spall, J., Spall, A., Shah, R.V., Kaye, A.D., «Cannabidiol (CBD) as a treatment of acute and chronic back pain: A case series and literature review», in: Journal of Opioid Management (Mai/Juni 2020) 16(3), S. 215–218.

Blake, D.R., Robson, P., Ho, M., Jubb, R.W., McCabe, C.S., «Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis», in: Rheumatology (Oxford) 45 (2006), 1, S. 50–52.

Naftali, T., Bar-Lev Schleider, L., Dotan, I., Lansky, E.P., Sklerovsky Benjaminov, F., Konikoff, F.M., «Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study», in: Clinical Gastroenterology and Hepatology 11 (2013), 10, S. 1276–1280.

Karsak, M., Gaffal, E., Date, R., Wang-Eckhardt, L., Rehnelt, J., Petrosino, S., Starowicz, K., Steuder, R., Schlicker, E., Cravatt, B., Mechoulam, R., Buettner, R., Werner, S., Di Marzo, V., Tüting, T., Zimmer, A., «Attenuation of allergic contact dermatitis through the endocannabinoid system», in: Science 316 (Juni 2007), 5830, S. 1494–1497.

Ellis, R.J., Peterson, S., Cherner, M., Morgan, E., Schrier, R., Tang, B., Hoenigl, M., Letendre, S., Iudicello, J., «Beneficial Effects of Cannabis on Blood Brain Barrier Function in HIV», in: Clinical Infectious Diseases (2020), ciaa437.

Kozela, E., Juknat, A., Gao, F., Kaushansky, N., Coppola, G., Vogel, Z., «Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells», in: Journal of Neuroinflammation 13 (2016), 1, S. 136.

Kozela, E., Juknat, A., Kaushansky, N., Rimmerman, N., Ben-Nun, A., Vogel, Z., «Cannabinoids decrease the th17 inflammatory autoimmune phenotype», in: Journal of Neuroimmune Pharmacology 8 (2013), 5, S. 1265–12676.

Hobbs, J.M., Vazquez, A.R., Remijan, N.D., Trotter, R.E., McMillan, T.V., Freedman, K.E., Wie, Y., Woelfel, K.A., Arnold, O.R., Wolfe, L.M., Johnson, S.A., Weir, T.L., «Evaluation of pharmacokinetics and acute anti-inflammatory potential of two oral cannabidiol preparations in healthy adults», in: Phytotherapy Research, 8. März 2020.

Costiniuk, C.T., Jenabian, M.A., «Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment?», in: Cytokine & Growth Factor Reviews (2020), 53, S. 63–65.

Couch, D.G., Tasker, C., Theophilidou, E., Lund, J.N., O’Sullivan, S.E., «Cannabidiol and palmitoylethanolamide are anti-inflammatory in the acutely inflamed human colon», in: Clinical Science (London) 131 (2017), 21, S. 2611–2626.

Yeshurun, M., Shpilberg, O., Herscovici, C., Shargian, L., Dreyer, J., Peck, A., Israeli, M., Levy-Assaraf, M., Gruenewald, T., Mechoulam, R., Raanani, P., Ram, R., «Cannabidiol for the prevention of Graft-versus-Host-Disease after allogeneic hematopoietic cell transplantation: results of a phase II study», in: Biology of Blood and Marrow Transplantation 21 (2015), 10, S. 1770–1775.

Collin, C., Davies, P., Mutiboko, I.K., Ratcliffe, S., für die Sativex Spasticity in MS Study Group, «Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis», in: European Journal of Neurology 14 (2007), 3, S. 290–296.

Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O’Leary, C., Ratcliffe, S., Nováková, I., Zapletalova, O., Piková, J., Ambler, Z., «A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis», in: Neurological Research 32 (2010), 5, S. 451–459.

Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., Gasperini, C., Pozzilli, C., Cefaro, L., Comi, G., Rossi, P., Ambler, Z., Stelmasiak, Z., Erdmann, A., Montalban, X., Klimek, A., Davies, P.; Sativex Spasticity Study Group, «A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis», in: European Journal of Neurology 18 (2011), 9, S. 1122–1131.

Riva, N., Mora, G., Sorarù, G., Lunetta, C., Ferraro, O.E., Falzone, Y., Leocani, L., Fazio, R., Comola, M., Comi, G.; CANALS Study Group, «Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial», in: The Lancet Neurology 18 (2019), 2, S. 155–164.

Clifford, D.B., «Tetrahydrocannabinol for tremor in multiple sclerosis», in: Annals of Neurology 13 (1983), S. 669–671.

Müller-Vahl, K.R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., Emrich, H.M., «Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial», in: Journal of Clinical Psychiatry 64 (2003), 4, S. 459–465.

Beckmann, Y., Seçil, Y., Güngör, B., Yiğit, T., «Tardive dystonia and the use of cannabis», in: Turk Psikiyatri Dergisi 21 (2010), 1, S. 90f.

Farooq, M.U., Ducommun, E., Goudreau, J., «Treatment of a hyperkinetic movement disorder during pregnancy with dronabinol», in: Parkinsonism and Related Disorders 15 (2009), 3, S. 249–251.

Ghorayeb, I., «More evidence of cannabis efficacy in restless legs syndrome», in: Sleep and Breathing 24 (2020), 1, S. 277–279.

Consroe, P.F., Wood, G.C., Buchsbaum, H., «Anticonvulsant nature of marihuana smoking», The Journal of the American Medical Association 234 (1975), 3, S. 306f.

Hegde, M., Santos-Sanchez, C., Hess, C.P., Kabir, A.A., Garcia, P.A., «Seizure exacerbation in two patients with focal epilepsy following marijuana cessation», in: Epilepsy and Behavior 25 (2012), 4, S. 563–566.

Devinsky, O., Cross, J.H., Laux, L., Marsh, E., Miller, I., Nabbout, R., Scheffer, I.E., Thiele, E.A., Wright, S., «Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome», in: The New England Journal of Medicine 376 (2017), 21, S. 2011–2020.

Snider, S.R., Consroe, P., «Treatment of Meige’s syndrome with cannabidiol», in: Neurology 34 (1984), (Suppl), S. 147.

Consroe, P., Sandyk, R., Snider, S.R., «Open label evaluation of cannabidiol in dystonic movement disorders», in: International Journal of Neuroscience 30 (1986), 4, S. 277–282.

Hampson, A.J., Grimaldi, M., «Cannabinoid receptor activation and elevated cyclic AMP reduce glutamate neurotoxicity», in: European Journal of Neuroscience 13 (April 2001), 8, S. 1529–1536.

Firsching, R., Piek, J., Skalej, M., Rohde, V., Schmidt, U., Striggow, F.; the KN38-7271 Study Group, «Early survival of comatose patients after severe traumatic brain injury with the dual cannabinoid CB1/CB2 receptor agonist KN38-7271: a randomized, double-blind, placebo-controlled phase II trial, in: Journal of Neurological Surgery Part A: Central European Neurosurgery 73 (August 2012), 4, S. 204–216.

Lotan, I., Treves, T.A., Roditi, Y., Djaldetti, R., «Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study», in: Clinical Neuropharmacology 37 (2014), 2, S. 41–44.

Saft, C., von Hein, S.M., Lücke, T., Thiels, C., Peball, M., Djamshidian, A., Heim, B., Seppi, K., «Cannabinoids for treatment of dystonia in Huntington’s disease», in: Journal of Huntington’s Disease 7 (2018), 2, S. 167–173.

Lafuente, H., Pazos, M.R., Alvarez, A., Mohammed, N., Santos, M., Arizti, M., Alvarez, F.J., Martinez-Orgado, J.A., «Effects of cannabidiol and hypothermia on short-term brain damage in new-born piglets after acute hypoxia-Iichemia»; in: Frontiers in Neuroscience 10 (2016), S. 323.

Ceprián, M., Jiménez-Sánchez, L., Vargas, C., Barata, L., Hind, W., Martínez-Orgado, J., «Cannabidiol reduces brain damage and improves functional recovery in a neonatal rat model of arterial ischemic stroke», in: Neuropharmacology 116 (2017), S. 151–159.

Perez, M., Benitez, S.U., Cartarozzi, L.P., Del Bel, E., Guimarães, F.S., Oliveira, A.L., «Neuroprotection and reduction of glial reaction by cannabidiol treatment after sciatic nerve transection in neonatal rats», in: European Journal of Neuroscience 38 (2013), 10, S. 3424–3434.

Nahler, J., «Co-medication with cannabidiol may slow down the progression of motor neuron disease: a case report», in: Journal of General Practice (Los Angeles) 5 (2017), S. 4.

Watt, G., Shang, K., Zieba, J., Olaya, J., Li, H., Garner, B., Karl, T., «Chronic Treatment with 50 mg/kg Cannabidiol Improves Cognition and Moderately Reduces Aß42 Levels in 12-Month-Old Male AßPPswe/PS1ΔE9 Transgenic Mice», in: Journal of Alzheimer’s Disease 74 (2020), 3, S. 937–950.

Aso, E., Andrés-Benito, P., Ferrer, I., «Delineating the efficacy of a cannabis-based medicine at advanced stages of dementia in a murine model, in: Journal of Alzheimer’s Disease 54 (2016), 3, S. 903–912.

Chagas, M.H., Zuardi, A.W., Tumas, V., Pena-Pereira, M.A., Sobreira, E.T., Bergamaschi, M.M., Dos Santos, A.C., Teixeira, A.L., Hallak, J.E., Crippa, J.A., «Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial, in: Journal of Psychopharmacology 28 (2014), 11, S. 1088–1098.

Cooper, R.E., Williams, E., Seegobin, S., Tye, C., Kuntsi, J., Asherson, P., «Cannabinoids in attention-deficit/hyperactivity disorder: a randomised-controlled trial», in: European Neuropsychopharmacology 27 (2017), 8, S. 795–808.

Schindler, F., Anghelescu, I., Regen, F., Jockers-Scherubl, M., «Improvement in refractory obsessive compulsive disorder with dronabinol», in: American Journal of Psychiatry 165 (2008), 4, S. 536f.

Karhson, D.S., Krasinska, K.M., Dallaire, J.A., Libove, R.A., Phillips, J.M., Chien, A.S., Garner, J.P., Hardan, A.Y., Parker, K.J., «Plasma anandamide concentrations are lower in children with autism spectrum disorder», in: Molecular Autism 9 (2018), S. 18.

Roitman, P., Mechoulam, R., Cooper-Kazaz, R., Shalev, A., «Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder», in: Clinical Drug Investigation 34 (2014), 8, S. 587–591.

Volicer, L., Stelly, M., Morris, J., McLaughlin, J., Volicer, B.J., «Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease», in: International Journal of Geriatric Psychiatry 12 (1997), S. 913–919.

Beal, J.E., Olson, R., Laubenstein, L., Morales, J.P., Bellman, P., Yangco, B., Lefkowitz, L., Plasse, T.F., Shepard, K.V., «Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS», in: Journal of Pain and Symptom Management 10 (1995), 2, S. 89–97. Regelson, W., Butler, J.R., Schulz, J., Kirk, T., Peek, L., Green, M.L., Zalis, M.O., «Delta-9-tetrahydrocannabinol as an effective antidepressant and appetite-stimulating agent in advanced cancer patients», in: Braude, M.C., Szara, S. (Hrsg.), Pharmacology of Marihuana, Bd. 2, New York 1976: Raven Press, S. 763–776.

Anderson, S.P., Zylla, D.M., McGriff, D.M., Arneson, T.J., «Impact of Medical Cannabis on Patient-Reported Symptoms for Patients With Cancer Enrolled in Minnesota’s Medical Cannabis Program», in: Journal of Oncology Practice 15 (2019), 4, e338–e345.

Poli, P., Crestani, F., Salvadori, C., Valenti, I., Sannino, C., «Medical Cannabis in Patients with Chronic Pain: Effect on Pain Relief, Pain Disability, and Psychological aspects. A Prospective Non randomized Single Arm Clinical Trial», in: Clinical Therapeutics 169 (2018), 3, e102–e107.

Li, X., Diviant, J.P., Stith, S.S., Brockelman, F., Keeling, K., Hall, B., Vigil, J.M., «The Effectiveness of Cannabis Flower for Immediate Relief from Symptoms of Depression», in: Yale Journal of Biology & Medicine (2020), S. 251–264.

Schwarcz, G., Karajgi, B., «Improvement in refractory psychosis with dronabinol: four case reports», in: Journal of Clinical Psychiatry 71 (2010), 11, S. 1552–1553.

«Medicinal Cannabis Effective for Chronic Insomnia in Clinical Trial», in: Practical Neurology, 4. Juni 2020.

Fronmüller, B. (1869), «Klinische Studien über die schlafmachende Wirkung der narkotischen Arzneimittel», Erlangen, 1869, S. 69.

Lichtman, A.H., Sheikh, S.M., Loh, H.H., Martin, B.R., «Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice», in: Journal of Pharmacology and Experimental Therapeutics 298 (2001), 3, S. 1007–1014.

Mikuriya, T.H., «Cannabis substitution: an adjunctive therapeutic tool in the treatment of alcoholism», in: Medical Times 98 (1970), 4, S. 187–191.

Koff, W.C., «Marijuana and sexual activity», in: The Journal of Sex Research 10 (1974), 3, S. 194–204.

Fantus, R.J., Lokeshwar, S.D., Kohn, T.P., Ramasamy, R., «The effect of tetrahydrocannabinol on testosterone among men in the United States: results from the National Health and Nutrition Examination Survey», in: World Journal of Urology, 17. Februar 2020.

Grimm, O., Löffler, M., Kamping, S., Hartmann, A., Rohleder, C., Leweke, M., Flor, H., «Probing the endocannabinoid system in healthy volunteers: Cannabidiol alters fronto-striatal resting-state connectivity», in: European Neuropsychopharmacology 28 (2018), 7, S. 841–849.

Leweke, F.M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C.W., Hoyer, C., Klosterkötter, J., Hellmich, M., Koethe, D., «Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia», Translational Psychiatry 2 (2012), e94.

McGuire, P., Robson, P., Cubala, W.J., Vasile, D., Morrison, P.D., Barron, R., Taylor, A., Wright, S., «Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial», in: American Journal of Psychiatry 175 (2018), 3, S. 225–231.

Bergamaschi, M.M., Queiroz, R.H., Chagas, M.H., de Oliveira, D.C., De Martinis, B.S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A.E., Martín-Santos, R., Hallak, J.E., Zuardi, A.W., Crippa, J.A., «Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients», in: Neuropsychopharmacology 36 (2011) 6, S. 1219–1226.

Elms, L., Shannon, S., Hughes, S., Lewis, N., «Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series», in: Journal of Alternative and Complementary Medicine 25 (2019), 4, S. 392–397.

Linge, R., Jiménez-Sánchez, L., Campa, L., Pilar-Cuéllar, F., Vidal, R., Pazos, A., Adell, A., Díaz, Á., «Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors», in: Neuropharmacology 103 (2016), S. 16–26.

Nicholson, A.N., Turner, C., Stone, B.M., Robson, P.J., «Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early- morning behavior in young adults», in: Journal of Clinical Psychopharmacology 24 (2004), 3, S. 305–313.

Consroe, P., Sandyk, R., Snider, S.R., «Open label evaluation of cannabidiol in dystonic movement disorders», in: International Journal of Neuroscience 30 (1986), 4, S. 277–282.

Belendiuk, K.A., Babson, K.A., Vandrey, R., Bonn-Miller, M.O., «Cannabis species and cannabinoid concentration preference among sleep-disturbed medicinal cannabis users», in: Addictive Behaviors 50 (2015), S. 178–181.

Hurd, Y.L., Spriggs, S., Alishayev, J., Winkel, G., Gurgov. K., Kudrich, C., Oprescu, A.M., Salsitz, E., «Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial», in: American Journal of Psychiatry 176 (2019), 11, S. 911–922.

Crippa, J.A., Hallak, J.E., Machado-de-Sousa, J.P., Queiroz, R.H., Bergamaschi, M., Chagas, M.H., Zuardi, A.W., «Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report», in: Journal of Clinical Pharmacy and Therapeutics 38 (2013), 2, S. 162–164.

Laczkovics, C., Kothgassner, O.D., Felnhofer, A., Klier, C.M., «Cannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression», in: Neuropsychiatry, 12. Februar 2020.

Casarotto, P.C., Gomes, F.V., Resstel, L.B., Guimarães, F.S., «Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors», in: Behavioural Pharmacology 21 (2010), 4, S. 353–358.

Fleury-Teixeira, P., Caixeta, F.V., Ramires da Silva, L.C., Brasil-Neto, J.P., Malcher-Lopes, R., «Effects of CBD-Enriched Cannabis Sativa Extract on Autism Spectrum Disorder Symptoms: An Observational Study of 18 Participants Undergoing Compassionate Use», in: Frontiers in Neurology 10 (2019), S. 1145.